Anthera Pharma (ANTH) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. PTC
2. PCVX
3. NVDA
4. SPY
5. META
6. MSFT
7. RXO
8. GOOGL
9. GMAB
10. BETR

Go back to Anthera Pharma (ANTH) Misses Q1 EPS by 1c

Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial Results

May 9, 2016 8:38 AM EDT

SOLUTION clinical study of Sollpura expanded to Europe, Israel and Canada in addition to ongoing US enrollmentCraig Thompson named as President and Chief Operating OfficerAppointment of Dr. James Pennington to Interim Chief Medical OfficerEnrollment of BRIGHT-SC Phase 2 clinical study in IgA Nephropathy completedBulk manufacturing campaign for blisibimod completed for CHABLIS-7.5

HAYWARD, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today provided a business update and reported financial results for the first quarter ended March 31, 2016.

Recent Developments and Business Highlights:

Sollpura (liprotamase)... More